CompletedPhase 2NCT05564637

A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension

Studying Drug- or toxin-induced pulmonary arterial hypertension

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Mayo Clinic
Principal Investigator
Yogesh N Reddy, M.B.B.S
Mayo Clinic
Intervention
Treprostinil(drug)
Enrollment
29 enrolled
Eligibility
18 years · All sexes
Timeline
20232024

Study locations (1)

Collaborators

United Therapeutics

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05564637 on ClinicalTrials.gov

Other trials for Drug- or toxin-induced pulmonary arterial hypertension

Additional recruiting or active studies for the same condition.

See all trials for Drug- or toxin-induced pulmonary arterial hypertension

← Back to all trials